CN
About Ribo
About Ribo
International R&D Center
Our Story
Leadership Team
Scientific Advisory Board
News
Science
About Oligonucleotide Therapeutics
Technological Innovations
Intellectual Property
Pipeline
Therapeutic Area
Pipeline
Products
Clinical Trials
Collaboration
BD and Collaboration
Careers
Our Culture
Career Development
Recruitment
Contact Information
Contact Information
About Ribo
Science
Pipeline
Collaboration
Careers
Contact Information
About Ribo
International R&D Center
Our Story
Leadership Team
Scientific Advisory Board
News
About Oligonucleotide Therapeutics
Technological Innovations
Intellectual Property
Therapeutic Area
Pipeline
Products
Clinical Trials
BD and Collaboration
Our Culture
Career Development
Recruitment
Contact Information
CN
Search
News
About Ribo
International R&D Center
Our Story
Leadership Team
Scientific Advisory Board
News
About Ribo
News
Ribo Closed $40M Series E1 Financing to support global development of the diversified pipelines and continuous advancement of siRNA technologies.
Jul 29,2022
Last : Ribo Announces China CDE Approval of Clinical Trial Application of RBD7022 First-In-Human Clinical Trial in China for Treatment of Hyperlipidemia.
Next : Ribocure Pharmaceuticals Moves Into GoCo Clinic - Putting North Europe in the Spotlight Within Oligonucleotide Therapeutics
Jul 29,2022
